$80.97
5.61% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US92243G1085
Symbol
PCVX
Sector
Industry

Vaxcyte Inc Stock price

$80.97
-13.01 13.84% 1M
+2.20 2.79% 6M
+18.17 28.93% YTD
+17.56 27.69% 1Y
+57.88 250.67% 3Y
+54.82 209.64% 5Y
+54.82 209.64% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-4.81 5.61%
ISIN
US92243G1085
Symbol
PCVX
Sector
Industry

Key metrics

Market capitalization $10.09b
Enterprise Value $7.94b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.95
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-529.05m
Free Cash Flow (TTM) Free Cash Flow $-616.24m
Cash position $2.18b
EPS (TTM) EPS $-4.68
P/E forward negative
Short interest 10.05%
Show more

Is Vaxcyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Vaxcyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Vaxcyte Inc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Vaxcyte Inc forecast:

Buy
100%

Financial data from Vaxcyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 14 14
47% 47%
-
-14 -14
47% 47%
-
- Selling and Administrative Expenses 54 54
49% 49%
-
- Research and Development Expense 447 447
60% 60%
-
-515 -515
58% 58%
-
- Depreciation and Amortization 14 14
47% 47%
-
EBIT (Operating Income) EBIT -529 -529
58% 58%
-
Net Profit -508 -508
69% 69%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vaxcyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxcyte Inc Stock News

Neutral
GlobeNewsWire
10 days ago
NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Vaxcyte, Inc. (NASDAQ: PCVX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Neutral
GlobeNewsWire
26 days ago
-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five --
Neutral
GlobeNewsWire
about 2 months ago
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 --
More Vaxcyte Inc News

Company Profile

Vaxcyte, Inc., a biopharmaceutical company, develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate, and complex antigen-based vaccines. The company has a license to Sutro Biopharma's Xpress CF platforms for cell free protein synthesis and site-specific conjugation. Vaxcyte, Inc. was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May, 2020. The company was incorporated in 2013 and is headquartered in Foster City, California.

Head office United States
CEO Grant Pickering
Employees 254
Founded 2013
Website www.vaxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today